CMS Should Retain Existing Part D Protected Classes, Senate Finance Committee Urges
This article was originally published in The Pink Sheet Daily
Executive Summary
A letter signed by the entire Senate committee questions CMS’ reasons for dropping antidepressants and antipsychotic drugs from protected status in the Medicare Part D program, arguing it could end up increasing costs to the program.